Skip To Main Content
Christine Lacabaratz on Muck Rack

Christine Lacabaratz

As seen in: Nature, The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christine

Contact Christine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers

|
By Yves Lévy, Christiane Moog, Aurélie Wiedemann, Odile Launay, Fabio Candotti, Lucile Hardel, Boris P Hejblum, Alpha A. Diallo, Christine Lacabaratz, Sylvain Cardinaud, Sandra Zurawski, Gerard Zurawski, Georgia Tomaras, Rodolphe Thiébaut, Giuseppe Pantaleo, Jean-Daniel Lelièvre, Laura Richert, Mélany Durand, Véronique Rieux, Mireille Centlivre
| Nature Verified
Abstract The ANRS VRI06 trial investigated CD40.HIVRI.Env, an Antibody Mediated Vaccine composed by a CD40 monoclonal antibody fused with gp140 Env, designed to target antigen to dendritic cells. Initial results in 72 HIV-uninfected volunteers showed that administration of 0.3-3.0 mg of CD40.HIVRI.Env, given alone or with DNA-HIV-PT123, was safe and immunogenic up to 48 weeks.
Open in Who Shared Issue with article?

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases - Nature Communications

|
By Aurélie Wiedemann, Edouard Lhomme, Christine Lacabaratz, Rodolphe Thiébaut, Yves Lévy
| Nature Verified
Abstract Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck’s Ervebo (rVSV-ZEBOV) and Johnson & Johnson’s two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up of the PREVAC randomized trial (NCT02876328), we report the results of the immunology ancillary study of the trial.
Open in Who Shared Issue with article?

T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial

|
By Laura Richert, Jean-Daniel Lelièvre, Christine Lacabaratz, Lucile Hardel
| The Journal of Immunology Verified
Conceptualization, L.R., J.-D.L., R.T., and Y.L.; data curation, C. Lacabaratz, L.H., A.W., H.H., A.D., C.B., E.R., and M.D.; formal analysis, L.R., C.B., M.D., B.H., and R.T.; funding acquisition, Y.L.; investigation, J.-D.L., O.L., F.L., I.P.-M., C. Lacabaratz, A.W., H.H., A.D., M.S., C. Lefebvre, E.F., P.T., and L.G.; methodology, L.R. and R.T.; project administration, L.R., J.-D.L., L.H., V.R., and Y.L.; resources: software, B.H.; supervision, L.R., J.-D.L., R.T., and Y.L.; validation: C.
Open in Who Shared Issue with article?
See all 3 articles